<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04159961</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ211101</org_study_id>
    <nct_id>NCT04159961</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety, Tolerability of DWJ211in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Parallel Design Clinical Trial to Evaluate the Safety/Tolerability and Pharmacokinetic of DWJ211 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, parallel design Phase I clinical trial to evaluate the
      safety/tolerability and pharmacokinetic of DWJ211 in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 16, 2019</start_date>
  <completion_date type="Anticipated">May 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0, 5, 10, 15, 30, 45min, 1, 1.5, 2, 4, 6, 8, 12, 16, 24h</time_frame>
    <description>Maximum concentration of DWJ211</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>0, 5, 10, 15, 30, 45min, 1, 1.5, 2, 4, 6, 8, 12, 16, 24h</time_frame>
    <description>Time of maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt</measure>
    <time_frame>0, 5, 10, 15, 30, 45min, 1, 1.5, 2, 4, 6, 8, 12, 16, 24h</time_frame>
    <description>Area under the drug concentration-time curve</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GroupA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inject the Drug into submental fat and abdominal fat via subcutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GroupB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inject the Drug into submental fat and abdominal fat via subcutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GroupC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inject the Drug into submental fat and abdominal fat via subcutaneous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWJ211</intervention_name>
    <description>Inject the Drug into submental fat and abdominal fat via subcutaneous</description>
    <arm_group_label>GroupA</arm_group_label>
    <arm_group_label>GroupB</arm_group_label>
    <arm_group_label>GroupC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult aged between 19 and 65 at screening

          -  Those whose BMI is less than 40kg/m2

          -  Subject who will agree with the no treatment(liposuction or surgery, obesity
             treatment)

          -  Those who are adequate to be subjects in this study upon judgment of the investigator
             after physical examination, clinical laboratory test, examination by interview, etc

        Exclusion Criteria:

          -  Those who have clinical significant liver, kidney, nervous system, respiratory,
             endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or
             past history

          -  History of any intervention to treat Submental fat or abdominal fat

          -  History or current symptoms of dysphagia

          -  History of trauma associated with the chin or neck or abdominal areas that in the
             judgement of the investigator may affect evaluation of safety or efficacy of treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>MIJUNG SONG</last_name>
    <phone>82-2-550-8368</phone>
    <email>mjsong257@daewoong.co.kr</email>
  </overall_contact>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 8, 2019</study_first_submitted>
  <study_first_submitted_qc>November 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>November 8, 2019</last_update_submitted>
  <last_update_submitted_qc>November 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

